Stock Events

Stock Events

Denali Therapeutics 

€16.66
50
+€0.17+1.03% Today

Statistics

Day High
15.73
Day Low
15.73
52W High
19.24
52W Low
10.17
Volume
-
Avg. Volume
-
Mkt Cap
2.64B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

12MayExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-0.8
-0.73
-0.66
-0.6
Expected EPS
-0.661848
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-882.71MNet Income

Analyst Ratings

$26.47Average Price Target
The highest estimate is 31.87.
From 10 ratings within the last 6 months. This is not an investment recommendation.
Buy
90%
Hold
10%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 4DN.F. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Biogen
BIIB
Mkt Cap22.63B
Biogen focuses on neurodegenerative diseases, directly competing with Denali's focus on neurological disorders.
Ionis Pharmaceuticals
IONS
Mkt Cap12.03B
Ionis Pharmaceuticals develops RNA-targeted therapies, including for neurological diseases, competing with Denali's approach.
Alnylam Pharmaceuticals
ALNY
Mkt Cap60.25B
Alnylam Pharmaceuticals works on RNAi therapeutics for genetic diseases, including neurodegenerative disorders, competing with Denali's focus.
Vertex Pharmaceuticals
VRTX
Mkt Cap109.11B
Vertex Pharmaceuticals, while known for cystic fibrosis treatments, is expanding into gene editing for neurological diseases, posing competition to Denali.
PTC Therapeutics
PTCT
Mkt Cap5.4B
PTC Therapeutics focuses on rare disorders, including neurological diseases, directly competing with Denali's market.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals, known for its broad portfolio, is increasingly focusing on treatments for neurological disorders.
Novartis
NVS
Mkt Cap237.61B
Novartis has a broad portfolio that includes treatments for neurological conditions, competing with Denali on multiple fronts.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.29B
BioMarin Pharmaceutical targets rare genetic diseases, some of which are neurological, overlapping with Denali's focus areas.
Arbutus Biopharma
ABUS
Mkt Cap906.73M
Arbutus Biopharma is engaged in the discovery and development of therapies for viral diseases and cancer, but its technology could be applied to neurological diseases, representing potential future competition.

About

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; DNL343 eIF2B activator program for amyotrophic lateral sclerosis; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome). Its Enzyme TransportVehicle (TV) programs include DNL952 for the treatment of Pompe disease; DNL111 for Parkinson's and Gaucher diseases; and DNL622 for Hurler syndrome (MPS I). The company's OTV programs also comprise DNL628 targeting tau for Alzheimer's disease; and DNL422 targeting alpha synuclein for Parkinson's disease, as well as antibody TV program includes DNL921 targeting Abeta for treating Alzheimer's disease. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
Show more...
CEO
Dr. Ryan J. Watts Ph.D.
Employees
486
Country
US
ISIN
US24823R1059
WKN
000A2H9G8

Listings

SA
BR
D2NL34.SA
XNAS
US
DNLI
F
DE
4DN.F
BOATS
BOATS
DNLI.BOATS

0 Comments

Share your thoughts

FAQ

What is Denali Therapeutics stock price today?▼
The current price of 4DN.F is €16.66 EUR — it has increased by +1.03% in the past 24 hours. Watch Denali Therapeutics stock price performance more closely on the chart.
What is Denali Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Denali Therapeutics stocks are traded under the ticker 4DN.F.
Is Denali Therapeutics stock price growing?▼
4DN.F stock has fallen by -10.45% compared to the previous week, the month change is a -6.9% fall, over the last year Denali Therapeutics has showed a +33.6% increase.
What is Denali Therapeutics market cap?▼
Today Denali Therapeutics has the market capitalization of 2.64B
When is the next Denali Therapeutics earnings date?▼
Denali Therapeutics is going to release the next earnings report on May 12, 2026.
What were Denali Therapeutics earnings last quarter?▼
4DN.F earnings for the last quarter are -0.62 EUR per share, whereas the estimation was -0.62 EUR resulting in a +0.93% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Denali Therapeutics revenue for the last year?▼
Denali Therapeutics revenue for the last year amounts to 0 EUR.
What is Denali Therapeutics net income for the last year?▼
4DN.F net income for the last year is -882.71M EUR.
How many employees does Denali Therapeutics have?▼
As of April 01, 2026, the company has 486 employees.
In which sector is Denali Therapeutics located?▼
Denali Therapeutics operates in the Health Care sector.
When did Denali Therapeutics complete a stock split?▼
Denali Therapeutics has not had any recent stock splits.
Where is Denali Therapeutics headquartered?▼
Denali Therapeutics is headquartered in South San Francisco, US.